康希诺亏损收窄超七成

国际金融报
26 Mar

3月25日晚间,昔日明星疫苗股康希诺发布的年报显示,2024年亏损收窄超七成。核心产品四价流脑结合疫苗曼海欣市占率不断提升,销量增长。3月26日,康希诺A股报收57.81元,跌0.67%;H股报收33.6港元,涨1.05%。流脑结合疫苗销售放量具体来看,康希诺全年实现营收8.46亿元,同比增长137.01%;归母净利润-3.79亿元,相较于去年的-14.83亿元,亏损收窄超七成。康希诺方面指出,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10